Why the study?
Patients with T2DM and HFpEF face an increased risk of cardiovascular events and mortality, prompting a review of HFpEF pathophysiology and SGLT2 inhibitor outcomes.
Do sodium-glucose cotransporter-2 (SGLT2) inhibitors improve outcomes in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction?
Do sodium-glucose cotransporter-2 (SGLT2) inhibitors improve outcomes in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction?
This review highlights the pathophysiological link between T2DM and HFpEF and the beneficial role of SGLT2 inhibitors in improving outcomes for this patient population.
May inform SGLT2i selection in T2DM-HF; leaves open dedicated HFpEF mortality trials.
Previous research has demonstrated that patients with type 2 diabetes (T2DM) are at an increased risk for cardiovascular events, including heart failure (HF). Moreover, there is a higher risk of mortality in individuals who have both T2DM and HF with preserved ejection fraction (HFpEF). Although there are antidiabetic agents that have shown both cardiovascular safety and improved cardiovascular outcomes, only certain agents have been associated with HF benefits, such as sodium-glucose cotransporter-2 (SGLT2) inhibitors. This study aims to review the pathophysiology of HFpEF in the setting of T2DM and, more specifically, the role of SGLT2 inhibitors in HFpEF outcomes.
No takes yet. Share an insight, caveat, or question.
Palaguachi et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: